MAP2K7 and lymphoma: Moreover, a recent study showed that the burton tyrosine kinase inhibitor ibrutinib, which has been approved by the FDA for the treatment of lymphoma and chronic lymphocytic leukemia, is an MKK7 inhibitor that can inhibit the ASK1/JNK pathway38.